{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:03:12Z","timestamp":1784685792778,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["IDF 2021"],"award-info":[{"award-number":["IDF 2021"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Legs Poix","award":["2021"],"award-info":[{"award-number":["2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04437-5","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T18:54:36Z","timestamp":1779648876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung Cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Paul","family":"Takam Kamga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Capron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Glorion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Julie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"1","key":"4437_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4437_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4437_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537\u2013546. https:\/\/doi.org\/10.1200\/JCO.18.00149. (PubMed PMID: 30620668)","journal-title":"J Clin Oncol"},{"issue":"14","key":"4437_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38(14):1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136. (PubMed PMID: 32150489)","journal-title":"J Clin Oncol"},{"issue":"11","key":"4437_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J et al (2023) Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the Phase III KEYNOTE-407 study. J Clin Oncol 41(11):1999\u20132006. https:\/\/doi.org\/10.1200\/JCO.22.01990. (PubMed PMID: 36735893; PubMed Central PMCID: PMC10082300)","journal-title":"J Clin Oncol"},{"key":"4437_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2406063","author":"J Yao","year":"2024","unstructured":"Yao J, Lin X, Zhang X, Xie M, Ma X, Bao X et al (2024) Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2024.2406063","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"4437_CR7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D et al (2022) Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 17(12):1335\u20131354. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.109. (PubMed PMID: 36184066)","journal-title":"J Thorac Oncol"},{"issue":"9","key":"4437_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers11091269","volume":"11","author":"A Costantini","year":"2019","unstructured":"Costantini A, TakamKamga P, Dumenil C, Chinet T, Emile JF, Giroux Leprieur E (2019) Plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: new tools for better patient selection? Cancers 11(9):9. https:\/\/doi.org\/10.3390\/cancers11091269","journal-title":"Cancers"},{"issue":"18","key":"4437_CR9","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3390\/cancers15184503","volume":"15","author":"G Dal Collo","year":"2023","unstructured":"Dal Collo G, TakamKamga P (2023) Unlocking the potential of biomarkers for immune checkpoint inhibitors in cancer therapy. Cancers Basel 15(18):4503. https:\/\/doi.org\/10.3390\/cancers15184503. (PubMed PMID: 37760473; PubMed Central PMCID: PMC10526481)","journal-title":"Cancers Basel"},{"issue":"11","key":"4437_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36(11):1461\u20131473. https:\/\/doi.org\/10.1038\/onc.2016.304. (PubMed PMID: 27617575; PubMed Central PMCID: PMC5357762.)","journal-title":"Oncogene"},{"issue":"2","key":"4437_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","volume":"52","author":"YS Jung","year":"2020","unstructured":"Jung YS, Park JI (2020) Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex. Exp Mol Med 52(2):183\u2013191. https:\/\/doi.org\/10.1038\/s12276-020-0380-6","journal-title":"Exp Mol Med"},{"issue":"1","key":"4437_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X et al (2022) Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7(1):1\u201323. https:\/\/doi.org\/10.1038\/s41392-021-00762-6","journal-title":"Signal Transduct Target Ther"},{"key":"4437_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02854","author":"E Martin-Orozco","year":"2019","unstructured":"Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, Ayala-San Nicolas M (2019) WNT signaling in tumors: the way to evade drugs and immunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02854","journal-title":"Front Immunol"},{"issue":"1","key":"4437_CR14","doi-asserted-by":"publisher","first-page":"e000527","DOI":"10.1136\/jitc-2020-000527","volume":"8","author":"E Giroux Leprieur","year":"2020","unstructured":"Giroux Leprieur E, H\u00e9lias-Rodzewicz Z, TakamKamga P, Costantini A, Julie C, Corjon A et al (2020) Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. J Immunother Cancer 8(1):e000527. https:\/\/doi.org\/10.1136\/jitc-2020-000527. (PubMed PMID: 32581058; PubMed Central PMCID: PMC7319709)","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4437_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.rmra.2019.11.081","volume":"12","author":"C Mehlman","year":"2020","unstructured":"Mehlman C, TakamKamga P, Julie C, Laza O, H\u00e9lias-Rodzewicz Z, Dumenil C et al (2020) Activation des voies Sonic Hedgehog et Wnt et efficacit\u00e9 de l\u2019immunoth\u00e9rapie chez les patients avec CBNPC de stade avanc\u00e9. Rev Mal Respir Actual 12(1):47. https:\/\/doi.org\/10.1016\/j.rmra.2019.11.081","journal-title":"Rev Mal Respir Actual"},{"key":"4437_CR16","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.lungcan.2023.107447","volume":"188","author":"P TakamKamga","year":"2024","unstructured":"TakamKamga P, Mayenga M, Sebane L, Costantini A, Julie C, Capron C et al (2024) Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 188:107447. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107447. (PubMed PMID: 38176297)","journal-title":"Lung Cancer"},{"issue":"2","key":"4437_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00262-024-03882-4","volume":"74","author":"A Akli","year":"2025","unstructured":"Akli A, TakamKamga P, Julie C, Capron C, Costantini A, Dumenil C et al (2025) Role of the HGF\/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Immunol Immunother 74(2):58. https:\/\/doi.org\/10.1007\/s00262-024-03882-4","journal-title":"Cancer Immunol Immunother"},{"key":"4437_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1 \u2013 update and clarification: from the RECIST Committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081. (PubMed PMID: 27189322; PubMed Central PMCID: PMC5737828)","journal-title":"Eur J Cancer"},{"issue":"9","key":"4437_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers12092696","volume":"12","author":"P TakamKamga","year":"2020","unstructured":"TakamKamga P, Dal Collo G, Cassaro A, Bazzoni R, Delfino P, Adamo A et al (2020) Small molecule inhibitors of microenvironmental Wnt\/\u03b2-catenin signaling enhance the chemosensitivity of acute myeloid leukemia. Cancers 12(9):9. https:\/\/doi.org\/10.3390\/cancers12092696","journal-title":"Cancers"},{"issue":"16","key":"4437_CR20","doi-asserted-by":"publisher","first-page":"21713","DOI":"10.18632\/oncotarget.7964","volume":"7","author":"P Takam Kamga","year":"2016","unstructured":"Takam Kamga P, Bassi G, Cassaro A, Midolo M, Di Trapani M, Gatti A et al (2016) Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget 7(16):21713\u201321727. https:\/\/doi.org\/10.18632\/oncotarget.7964. (PubMed PMID: 26967055; PubMed Central PMCID: PMC5008317)","journal-title":"Oncotarget"},{"key":"4437_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03206-4","author":"J Talb","year":"2022","unstructured":"Talb J, Takam Kamga P, Mayenga M, Costantini A, Juli\u00e9 C, Dumenil C et al (2022) Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-022-03206-4","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4437_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2003.10.020","volume":"207","author":"H Ohgaki","year":"2004","unstructured":"Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurrer MO (2004) APC mutations are infrequent but present in human lung cancer. Cancer Lett 207(2):197\u2013203. https:\/\/doi.org\/10.1016\/j.canlet.2003.10.020. (PubMed PMID: 15072829)","journal-title":"Cancer Lett"},{"issue":"31","key":"4437_CR23","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/sj.onc.1204557","volume":"20","author":"K Shigemitsu","year":"2001","unstructured":"Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y et al (2001) Genetic alteration of the \u03b2-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 20(31):4249\u20134257. https:\/\/doi.org\/10.1038\/sj.onc.1204557. (PubMed PMID: 11464291)","journal-title":"Oncogene"},{"issue":"1","key":"4437_CR24","doi-asserted-by":"publisher","first-page":"djt356","DOI":"10.1093\/jnci\/djt356","volume":"106","author":"DJ Stewart","year":"2014","unstructured":"Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106(1):djt356. https:\/\/doi.org\/10.1093\/jnci\/djt356. (PubMed PMID: 24309006)","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"4437_CR25","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.7150\/jca.32205","volume":"10","author":"LM Hess","year":"2019","unstructured":"Hess LM, Brnabic A, Mason O, Lee P, Barker S (2019) Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J Cancer 10(16):3717\u20133727. https:\/\/doi.org\/10.7150\/jca.32205. (PubMed PMID: 31333789; PubMed Central PMCID: PMC6636299)","journal-title":"J Cancer"},{"key":"4437_CR26","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.phrs.2021.105532","volume":"167","author":"K Shah","year":"2021","unstructured":"Shah K, Panchal S, Patel B (2021) Porcupine inhibitors: novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway. Pharmacol Res 167:105532. https:\/\/doi.org\/10.1016\/j.phrs.2021.105532. (PubMed PMID: 33677106)","journal-title":"Pharmacol Res"},{"key":"4437_CR27","doi-asserted-by":"publisher","first-page":"1486329","DOI":"10.3389\/fimmu.2025.1486329","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Guo X, Sun X, Liao J, Liu Q, Ye Y et al (2025) Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer. Front Immunol 16:1486329. https:\/\/doi.org\/10.3389\/fimmu.2025.1486329. (PubMed PMID: 40040705; PubMed Central PMCID: PMC11876966)","journal-title":"Front Immunol"},{"issue":"15","key":"4437_CR28","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.3390\/cancers14153622","volume":"14","author":"R Zagozdzon","year":"2022","unstructured":"Zagozdzon R, Winiarska M, Firczuk M (2022) Immune evasion as the main challenge for immunotherapy of cancer. Cancers 14(15):3622. https:\/\/doi.org\/10.3390\/cancers14153622. (PubMed PMID: 35892880; PubMed Central PMCID: PMC9330814)","journal-title":"Cancers"},{"issue":"2","key":"4437_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccell.2022.12.008","volume":"41","author":"G Li","year":"2023","unstructured":"Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S et al (2023) Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell 41(2):304-322.e7. https:\/\/doi.org\/10.1016\/j.ccell.2022.12.008. (PubMed PMID: 36638784; PubMed Central PMCID: PMC10286807)","journal-title":"Cancer Cell"},{"key":"4437_CR30","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.medidd.2021.100113","volume":"13","author":"W Zhu","year":"2022","unstructured":"Zhu W, Wang H, Zhu D (2022) Wnt\/\u03b2-catenin signaling pathway in lung cancer. Med Drug Discov 13:100113. https:\/\/doi.org\/10.1016\/j.medidd.2021.100113","journal-title":"Med Drug Discov"},{"issue":"8","key":"4437_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/atm-22-1317","volume":"10","author":"Y Feng","year":"2022","unstructured":"Feng Y, Wang Y, Guo K, Feng J, Shao C, Pan M et al (2022) The value of WNT5A as prognostic and immunological biomarker in pan-cancer. Ann Transl Med 10(8):466. https:\/\/doi.org\/10.21037\/atm-22-1317. (PubMed PMID: 35571400; PubMed Central PMCID: PMC9096401)","journal-title":"Ann Transl Med"},{"issue":"5","key":"4437_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1242\/dev.00324","volume":"130","author":"Y Yang","year":"2003","unstructured":"Yang Y, Topol L, Lee H, Wu J (2003) Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 130(5):1003\u20131015. https:\/\/doi.org\/10.1242\/dev.00324. (PubMed PMID: 12538525)","journal-title":"Development"},{"issue":"12","key":"4437_CR33","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1073\/pnas.1701464114","volume":"114","author":"K Kessenbrock","year":"2017","unstructured":"Kessenbrock K, Smith P, Steenbeek SC, Pervolarakis N, Kumar R, Minami Y et al (2017) Diverse regulation of mammary epithelial growth and branching morphogenesis through noncanonical Wnt signaling. Proc Natl Acad Sci U S A 114(12):3121\u20133126. https:\/\/doi.org\/10.1073\/pnas.1701464114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4437_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/s1535-6108(03)00268-x","volume":"4","author":"H Liang","year":"2003","unstructured":"Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A et al (2003) Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4(5):349\u2013360. https:\/\/doi.org\/10.1016\/s1535-6108(03)00268-x. (PubMed PMID: 14667502)","journal-title":"Cancer Cell"},{"issue":"2","key":"4437_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.bjc.6605174","volume":"101","author":"SL McDonald","year":"2009","unstructured":"McDonald SL, Silver A (2009) The opposing roles of Wnt-5a in cancer. Br J Cancer 101(2):209\u2013214. https:\/\/doi.org\/10.1038\/sj.bjc.6605174","journal-title":"Br J Cancer"},{"issue":"23","key":"4437_CR36","doi-asserted-by":"publisher","first-page":"17259","DOI":"10.1074\/jbc.M700075200","volume":"282","author":"SK Dissanayake","year":"2007","unstructured":"Dissanayake SK, Wade M, Johnson CE, O\u2019Connell MP, Leotlela PD, French AD et al (2007) The Wnt5A\/Protein Kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition*. J Biol Chem 282(23):17259\u201317271. https:\/\/doi.org\/10.1074\/jbc.M700075200","journal-title":"J Biol Chem"},{"issue":"3","key":"4437_CR37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.scr.2015.02.007","volume":"14","author":"JA Kim","year":"2015","unstructured":"Kim JA, Choi HK, Kim TM, Leem SH, Oh IH (2015) Regulation of mesenchymal stromal cells through fine tuning of canonical Wnt signaling. Stem Cell Res 14(3):356\u2013368. https:\/\/doi.org\/10.1016\/j.scr.2015.02.007","journal-title":"Stem Cell Res"},{"issue":"9","key":"4437_CR38","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2326-6066.CIR-14-0167","volume":"3","author":"A Holtzhausen","year":"2015","unstructured":"Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS et al (2015) Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res 3(9):1082\u20131095. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0167. (PubMed PMID: 26041736; PubMed Central PMCID: PMC4927300)","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"4437_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cells8091060","volume":"8","author":"G Barbero","year":"2019","unstructured":"Barbero G, Castro MV, Villanueva MB, Quezada MJ, Fern\u00e1ndez NB, DeMorrow S et al (2019) An autocrine Wnt5a loop promotes NF-\u03baB pathway activation and cytokine\/chemokine secretion in melanoma. Cells 8(9):9. https:\/\/doi.org\/10.3390\/cells8091060","journal-title":"Cells"},{"key":"4437_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.636568","journal-title":"Front Immunol"},{"issue":"10","key":"4437_CR41","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1111\/cas.15497","volume":"113","author":"J Nagasaki","year":"2022","unstructured":"Nagasaki J, Ishino T, Togashi Y (2022) Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci 113(10):3303\u20133312. https:\/\/doi.org\/10.1111\/cas.15497. (PubMed PMID: 35848888; PubMed Central PMCID: PMC9530865)","journal-title":"Cancer Sci"},{"issue":"2","key":"4437_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/sji.12075","volume":"78","author":"C Bergenfelz","year":"2013","unstructured":"Bergenfelz C, Janols H, Wullt M, Jirstr\u00f6m K, Bredberg A, Leandersson K (2013) Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation. Scand J Immunol 78(2):194\u2013204. https:\/\/doi.org\/10.1111\/sji.12075. (PubMed PMID: 23679576)","journal-title":"Scand J Immunol"},{"issue":"3","key":"4437_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/ATVBAHA.107.157438","volume":"28","author":"C Pereira","year":"2008","unstructured":"Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G (2008) Wnt5A\/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of Activated Protein C and Interleukin-10. Arterioscler Thromb Vasc Biol 28(3):504\u2013510. https:\/\/doi.org\/10.1161\/ATVBAHA.107.157438","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"4437_CR44","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41375-025-02616-4","volume":"39","author":"MK Hasan","year":"2025","unstructured":"Hasan MK, Widhopf li GF, Ghia EM, Kipps TJ (2025) Wnt5a induces ROR1 dependent NF-\u03baB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia. Leukemia 39(7):1661\u20131669. https:\/\/doi.org\/10.1038\/s41375-025-02616-4","journal-title":"Leukemia"},{"issue":"1","key":"4437_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41420-022-00884-y","volume":"8","author":"Y Guo","year":"2022","unstructured":"Guo Y, Pei H, Lu B, Zhang D, Zhao Y, Wu F et al (2022) Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia. Cell Death Discov 8(1):82. https:\/\/doi.org\/10.1038\/s41420-022-00884-y","journal-title":"Cell Death Discov"},{"issue":"30","key":"4437_CR46","doi-asserted-by":"publisher","first-page":"21028","DOI":"10.1074\/jbc.M113.546523","volume":"289","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Wang CL, Li RM, Hui TQ, Su YY, Yuan Q et al (2014) Wnt5a promotes inflammatory responses via nuclear factor \u03baB (NF-\u03baB) and Mitogen-activated Protein Kinase (MAPK) pathways in human dental pulp cells*. J Biol Chem 289(30):21028\u201321039. https:\/\/doi.org\/10.1074\/jbc.M113.546523","journal-title":"J Biol Chem"},{"issue":"1","key":"4437_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12964-020-00557-2","volume":"18","author":"Q Liu","year":"2020","unstructured":"Liu Q, Yang C, Wang S, Shi D, Wei C, Song J et al (2020) Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun Signal 18(1):51. https:\/\/doi.org\/10.1186\/s12964-020-00557-2","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4437_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S et al (2022) Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med 20(1):187. https:\/\/doi.org\/10.1186\/s12916-022-02356-7","journal-title":"BMC Med"},{"issue":"2","key":"4437_CR49","doi-asserted-by":"publisher","first-page":"e000678","DOI":"10.1136\/jitc-2020-000678","volume":"8","author":"A Keegan","year":"2020","unstructured":"Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A et al (2020) Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 8(2):e000678. https:\/\/doi.org\/10.1136\/jitc-2020-000678. (PubMed PMID: 33020238)","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4437_CR50","doi-asserted-by":"publisher","first-page":"935","DOI":"10.7150\/jca.81384","volume":"14","author":"Y Kim","year":"2023","unstructured":"Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B et al (2023) High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J Cancer 14(6):935\u2013942. https:\/\/doi.org\/10.7150\/jca.81384","journal-title":"J Cancer"},{"key":"4437_CR51","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.phrs.2021.105532","volume":"167","author":"K Shah","year":"2021","unstructured":"Shah K, Panchal S, Patel B (2021) Porcupine inhibitors: novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway. Pharmacol Res 167:105532. https:\/\/doi.org\/10.1016\/j.phrs.2021.105532","journal-title":"Pharmacol Res"},{"issue":"1","key":"4437_CR52","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41598-017-17539-z","volume":"8","author":"NK Lee","year":"2018","unstructured":"Lee NK, Zhang Y, Su Y, Bidlingmaier S, Sherbenou DW, Ha KD et al (2018) Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep 8(1):766. https:\/\/doi.org\/10.1038\/s41598-017-17539-z. (PubMed PMID: 29335534; PubMed Central PMCID: PMC5768681)","journal-title":"Sci Rep"},{"issue":"24","key":"4437_CR53","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1111\/bph.13894","volume":"174","author":"MH Kagey","year":"2017","unstructured":"Kagey MH, He X (2017) Rationale for targeting the Wnt signalling modulator Dickkopf\u20101 for oncology. Br J Pharmacol 174(24):4637\u20134650. https:\/\/doi.org\/10.1111\/bph.13894","journal-title":"Br J Pharmacol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04437-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:47:14Z","timestamp":1784684834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4437"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04437-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human samples were prospectively collected following written informed consent, in accordance with ethical approval granted in 2014 by the Institutional Review Board CPP IDF No. 8 (ID CRB 2014-A00187\u201340).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"194"}}